1. Мосолов С.Н. Обсессивно-компульсивное расстройство (диагностика, клиника, терапия): монография / С.Н. Мосолов. - М.: 2005. — 56 с.
2. Колюцкая Е.В., Смулевич А.Б. Невротические расстройства // Психиатрия: Научнопрактический справочник / Под ред. академика РАН А.С. Тиганова. — М.: ООО «Издательство «Медицинское информационное агентство». — 2016. — C. 349-368.
3. Abramowitz J.S. Obsessive-compulsive disorder / J.S. Abramowitz, S. Taylor, D. McKay // Lancet. - 2009. - Vol. - 374. — № 9688. - P. 491-499.
4. Milad M.R. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways / M.R. Milad, S.L. Rauch // Trends in Cognitive Sciences. — 2012. - Vol. 16. — №1. - P. 43-51.
5. Brain circuitry of compulsivity / O.A. van den Heuvel [et al.] // European Neuropsychopharmacology. - 2016. — Vol. 26. — №5. - P. 810-827.
6. Comorbidity, age of onset and suicidality in obsessive-compulsive disorder (OCD): An international collaboration / V. Brakoulias [et al.] // Comprehensive Psychiatry. - 2017. - Vol. 76. - P. 79-86.
7. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective / D.L. Pauls [et al.] // Nature Reviews. Neuroscience. - 2014. - Vol. 15. — №6. - P. 410424.
8. International Obsessive-Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS). Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis / MolecularPsychiatry.-2018.- Vol. 23. — №5. -P. 1181-1188.
9. Whole-genome association analysis of treatment response in obsessive-compulsive disorder / H. Qin [et al.] // Molecular Psychiatry. - 2016. - Vol. 21. — №2. - P. 270-276.
10. Genome-wide association study of obsessive-compulsive disorder / S.E. Stewart [et al.] // Molecular Psychiatry. - 2013. - Vol. 18. — №7. -P. 788-798.
11. Systematic review of environmental risk factors for Obsessive-Compulsive Disorder: A proposed roadmap from association to causation / G. Brander [et al.] // Neuroscience & Biobehavioral Reviews. - 2016. - Vol. 65. - P. 36-62.
12. Snider L.A. PANDAS: current status and directions for research / L.A. Snider, S.E. Swedo // Molecular Psychiatry. - 2004. — Vol. 9. - P. 900-907.
13. Moving from PANDAS to CANS / H.S. Singer [et al.] // The Journal of Pediatrics. - 2012. - Vol. 160. — №5. -P. 725-731.
14. Obsessive-compulsive disorder and female reproductive cycle events: results from the OCD and reproduction collaborative study / V. Guglielmi [et al.] // Depression and Anxiety. - 2014. - Vol. 31. — №12. -P. 979-987.
15. Fostick L. Acute obsessive-compulsive disorder (OCD) in veterans with posttraumatic stress disorder (PTSD) / L. Fostick, N. Nacasch, J. Zohar // World Journal of Biological Psychiatry. - 2012. - Vol. 13. — №4. - P. 312-315.
16. Coetzer B.R. Obsessive-compulsive disorder following brain injury: a review / B.R. Coetzer // International Journal of Psychiatry in Medicine. - 2004. - Vol. 34. — №4. - P. 363-377.
17. Neurosurgical targets for compulsivity: what can we learn from acquired brain lesions? / M. Figee [et al.] // Neuroscience and Biobehavioral Reviews. - 2013. - Vol. 37. — №3. - P. 328-339.
18. Dorsal anterior cingulotomy and anterior capsulotomy for severe, refractory obsessivecompulsive disorder: a systematic review of observational studies / L.T. Brown [et al.] // Journal of Neurosurgery. - 2016. - Vol. 124. — №1. - P. 77-89.
19. Ahmari S.E. Using mice to model Obsessive Compulsive Disorder: From genes to circuits / S.E. Ahmari // Neuroscience. - 2016. - Vol. 321. — P. 121-137.
20. Monteiro P. Learning From Animal Models of Obsessive-Compulsive Disorder / P. Monteiro, G. Feng // Biological Psychiatry. - 2016. - Vol. 79. — №1. - P. 7-16.
21. Multicenter voxel-based morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder / S.J. de Wit [et al.] // The American Journal of Psychiatry. — 2014. - Vol. 171. - №1. — P. 340-349.
22. Distinct Subcortical Volume Alterations in Pediatric and Adult OCD: A Worldwide Meta- and Mega-Analysis / P.S. Boedhoe [et al.] // The American Journal of Psychiatry. — 2017. - Vol. 174. — №1. - P. 60-69.
23. Insel T.R. Obsessive-compulsive disorder and serotonin: is there a connection? / T.R Insel // Biological Psychiatry. - 1985. — Vol. 20. — №11.- P. 1174-1188.
24. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder / M.S. Koo [et al.] // Expert Review of Neurotherapeutics. - 2010. — Vol. 10. — №2. - P. 275-290.
25. Pittenger C. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment / C. Pittenger, M.H. Bloch, K. Williams // Pharmacology & Therapeutics. - 2011. - Vol. 132. — №3. - P. 314-332.
26. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder / K. Wu [et al.] // Pharmacology, Biochemistry, and Behavior. - 2012. - 100. — №4. - P. 726-735.
27. Late-onset obsessive compulsive disorder: clinical characteristics and psychiatric comorbidity / Grant J.E. [et al.] // Psychiatry Research. - 2007. - Vol. 152. — №1. - P. 21-27.
28. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions / M.A. Fullana [et al.] // The American Journal of Psychiatry. - 2009. - Vol. 166. — №3. - P. 329-336.
29. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication / R.C. Kessler [et al.] // Archives of General Psychiatry. - 2005. - Vol. 62. — №6. - P. 617-627.
30. Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders / K.A. Phillips [et al.] // Depression and Anxiety. - 2007. - Vol. 24. — №6. - P. 399-409.
31. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication / A.M. Ruscio [et al.] // Molecular Psychiatry. - 2010. — Vol. 15. — №1. - P. 53-63.
32. The cross-national epidemiology of obsessive-compulsive disorder. The Cross-National Collaborative Group / M.M. Weissman [et al.] // The Journal of Clinical Psychiatry. - 1994.-Vol. 55. - Suppl. 5-10.
33. Pinto A. Personality features of OCD and spectrum conditions. In: The Oxford Handbook of Obsessive Compulsive and Spectrum Disorders, Steketee G (Ed) / A. Pinto, J.L.Eisen. — New York: Oxford University Press, 2012.
34. Clinical features of tic-related obsessive-compulsive disorder: results from a large multicenter study / P. Gomes de Alvarenga [et al.] // CNS Spectrums. - 2012. - Vol. 17. - №2. — P. 87-93.
35. Is obsessive-compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective / O.J. Bienvenu [et al.] // Psychological Medicine. - 2012. - Vol. 42. — №1. - P. 1-13.
36. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association / A.M. Achim [et al.] // Schizophrenia Bulletin. - 2011. — Vol. 37. — №4. - P. 811-821.
37. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications / Pallanti S. [et al.] // Frontiers in Psychiatry. - 2011. - Vol. 2. - P. 70.
38. Comorbidity of anxiety disorders with anorexia and bulimia nervosa / W.H. Kaye [et al.] // The American Journal of Psychiatry. - 2004. - Vol. 16. — №12. — P. 2215-2221.
39.The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. The ICD-10 classification of mental and behavioural disorders / W.H. Organization. - World Health Organization, 1993.
40. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) / American Psychiatric Association, Arlington, VA, 2013.
41. Obsessive-compulsive disorder with poor insight: a three-year prospective study / F. Catapano [et al.] // Progress in Neuropsychopharmacology & Biological Psychiatry. - 2010. - Vol. 34. - P. 323-330.
42. A 2-year prospective follow-up study of the course of obsessive-compulsive disorder / J.L. Eisen [et al.] // Journal of Clinical Psychiatry. - 2010. - Vol. 71. - №8. — P. 10331039.
43. DSM-IV field trial: obsessive-compulsive disorder / E.B. Foa [et al.] // The American Journal of Psychiatry. - 1995. — Vol. 152. — №1. - P. 90-96.
44. Phenomenology of OCD: lessons from a large multicenter study and implications for ICD-11 / Shavitt R.G. [et al.] // Journal of Psychiatric Research. - 2014. — Vol. 57. - P. 141-148.
45. Psychometric validation of the obsessive belief questionnaire and interpretation of intrusions inventory--Part 2: Factor analyses and testing of a brief version / Obsessive Compulsive Cognitions Working Group // Behavioral Research and Therapy. - 2005. - Vol. 43. — №11. - P. 1527-1542.
46. Suicidality in obsessive compulsive disorder (OCD): a systematic review and metaanalysis / I. Angelakis [et al.] // Clinical Psychology Review. - 2015. - Vol. 39. - P. 1-15.
47. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V / J.F. Leckman [et al.] // Depression and Anxiety. - 2010. - Vol. 27. — №6. - P. 507-527.
48. Skoog G. A 40-year follow-up of patients with obsessive-compulsive disorder / G. Skoog, I. Skoog // Archives of General Psychiatry. - 1999. - Vol. 56. — №2. - P. 121-127.
49. Response versus remission in obsessive-compulsive disorder / H.B. Simpson [et al.] // The Journal of Clinical Psychiatry. - 2006. - Vol. 67. — №2. — P. 269-276.
50. Quality of life and functional impairment in obsessive-compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls / J.D. Huppert [et al.] // Depression and Anxiety. - 2009. - Vol. 26. — №1. — P. 39-45.
51. Koran L.M. Quality of life for patients with obsessive-compulsive disorder / L.M. Koran, M.L. Thienemann, R. Davenport // The American Journal of Psychiatry. - 1996. - Vol.
153. - №6. - P. 783-788.
52. Quality of life and disability in patients with obsessive-compulsive disorder / J. Bobes [et al.] // European Psychiatry. - 2001. - Vol. 16. - №4. — P. 239-245.
53. Ravizza L. Episodic and chronic obsessive-compulsive disorder / L. Ravizza, G. Maina, F. Bogetto // Depression and Anxiety. - 1997. - Vol. 6. — №4. - P. 154-158.
54. The Yale-Brown Obsessive-Compulsive Scale. I. Development, use, and reliability / W.K. Goodman [et al.] // Archives of General Psychiatry. - 1989. - Vol. 46. — №11. - P. 10061011.
55. The Yale-Brown Obsessive-Compulsive Scale. II. Validity / W.K. Goodman [et al.] // Archives of General Psychiatry. - 1989. - Vol. 46. — №11. - P. 1012-1016.
56. Steketee G. The Yale-Brown Obsessive-Compulsive Scale: interview versus self-report / G. Steketee, R. Frost, K. Bogart // Behavior Research and Therapy. - 1996. - Vol. 34. — №8. - P. 675-684.
57. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scale / J.S. Abramowitz [et al.] // Psychological Assessment. - 2010. - Vol. 22. — №.1. - P. 180-198.
58. The OCI-R: validation of the subscales in a clinical sample / J.D. Huppert [et al.] // Journal of Anxiety Disorders. — 2007. — Vol. 21. — №3. - P. 394-406.
59. Florida Obsessive-Compulsive Inventory: development, reliability, and validity / E.A. Storch [et al.] // The Journal of Clinical Psychology. - 2007. - Vol. 63. — №9. - P. 851859.
60. Pharmacological and psychotherapeutic interventions for management of obsessivecompulsive disorder in adults: a systematic review and network meta-analysis / P. Skapinakis [et al.] // Lancet Psychiatry. - 2016. - Vol. 3. — №8. - P. 730-739.
61. Hirschtritt M.E. Obsessive-compulsive disorder: Advances in diagnosis and treatment / M.E. Hirschtritt, M.H. Bloch, C.A. Mathews // JAMA. - 2017. - Vol. 317. — № 13. - P. 1358-1367.
62. Pallanti, S. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines / S. Pallanti, L. Quercioli // Progress in Neuropsychopharmacology and Biological Psychiatry. - 2006. - Vol. 30. — №3. - P. 400-412.
63. Cottraux, J. Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder / J. Cottraux, M.A. Bouvard, M. Milliery // Cognitive Behavioral Therapy. - 2005. - Vol. 34. — №3. - P. 185-192.
64. Kaplan A. A review of pharmacologic treatments for obsessive-compulsive disorder / A. Kaplan, E. Hollander // Psychiatric Services. - 2003. - Vol. 54. — №8. - P. 1111-1118.
65. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder / H.B. Simpson [et al.] // Depression and Anxiety. - 2004. - Vol. 19. — №4. - P. 225-233.
66. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study / D.J. Stein [et al.] // Current Medical Research and Opinion. - 2007. - Vol. 23. — №4. - P. 701-711.
67. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) / G.M. Soomro [et al.] // Cochrane Database of Systematic Reviews. - 2008. - Vol. 1. — CD001765.
68. Early onset of response with selective serotonin reuptake inhibitors in obsessivecompulsive disorder: a meta-analysis / Y. Issari [et al.] // The Journal of Clinical Psychiatry. - 2016. - Vol. 77. — №5. - P. e605-e611.
69. Sustained response versus relapse: the pharmacotherapeutic goal for obsessivecompulsive disorder / N.A. Fineberg [et al.] // International Clinical Psychopharmacology. - 2007. - Vol. 22. — №6. - P. 313-322.
70. Escitalopram prevents relapse of obsessive-compulsive disorder / N.A. Fineberg [et al.] // European Neuropsychopharmacology. - 2007. - Vol. 17. — № 6-7. - P. 430-439.
71. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder / A. Landeros-Weisenberger [et al.] // Journal of Affective Disorders. - 2010. - Vol. 121. — №1-2. - P. 175-179.
72. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression / S. Saxena [et al.] // The American Journal of Psychiatry. - 2003. - Vol. 160. — №3. - P. 522-532.
73. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder / D. Mataix-Cols [et al.] // The American Journal of Psychiatry. - 1999. - Vol. 156. — №9. - P. 1409-1416.
74. Clinical predictors of drug response in obsessive-compulsive disorder / S. Erzegovesi [et al.] // Journal of Clinical Psychopharmacology. - 2001. - Vol. 21. — №5. - P. 488-492.
75. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder / R. Tukel [et al.] // Psychiatry and Clinical Neurosciences. - 2006. - Vol. 60. — №4. - P. 404-409.
76. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review / B. Dell’Osso [et al.] // The Journal of Clinical Psychiatry. - 2006. - Vol. 67. — №4. - P. 600-610.
77. Ackerman D.L., Greenland S. Multivariate Meta-Analysis of Controlled Drug Studies for Obsessive-Compulsive Disorder // J Clin Psychopharmacol. - 2002. - Vol. 22. — №3. - P. 309-317.
78. Obsessive-compulsive disorder: a double-blind placebo-controlled trial of clomipramine in 27 patients / M.A. Jenike [et al.] // The American Journal of Psychiatry. - 1989. - Vol. 146. — №10. - P. 1328-1330.
79. Clomipramine and obsessive-compulsive disorder: a placebo-controlled double-blind study of 32 patients / J.H. Greist [et al.] // The Journal of Clinical Psychiatry. - 1990. - Vol. 51. — №7. - P. 292-297.
80. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder / E.B. Foa [et al.] // The American Journal of Psychiatry. - 2005. - Vol. 162. — №1. - P. 151-161.
81. Zohar J. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder / J. Zohar, R. Judge // British Journal of Psychiatry. - 1996. - Vol. 169. — №4. - P. 468-474.
82. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study / U. Albert [et al.] // The Journal of Clinical Psychiatry. - 2002. — Vol. 63. — №11. - P. 1004-1009.
83. Rauch S.L. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases / S.L. Rauch, R.L. O’Sullivan, M.A. Jenike // Journal of Clinical Psychopharmacology. - 1996. - Vol. 16. — №1. - P. 81-84.
84. Sevincok, L. Venlafaxine open-label treatment of patients with obsessive-compulsive disorder / L. Sevincok, B. Uygur // The Australian and New Zealand Journal of Psychiatry. - 2002. - Vol. 36. — №6. - P. 817.
85. Venlafaxine in treatment-resistant obsessive-compulsive disorder / E. J. Hollandt al.] // The Journal of Clinical Psychiatry. - 2003. - Vol. 64. — №5. - P. 546-550.
86. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. // Arch Gen Psychiatry. - 1996. - Vol. 53 — №7. - P.653-654. doi:10.1001/archpsyc.1996.01830070103016.
87. Narayanaswamy JC, Viswanath B, Cherian AV. Venlafaxine in Treatment Resistant Obsessive-Compulsive Disorder // J Neuropsychiatry Clin Neurosci. - 2014 - Vol. 26. - №3. - P. 44-45
88. Denys D. et al. A double-blind comparison of venlafaxine and paroxetine in obsessivecompulsive disorder / D. Denys [et al.] // Journal of Clinical Psychopharmacology. - 2003. — Vol. 23. — №6. - P. 568-575.
89. Dell’osso B. et al. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive-compulsive disorder: a case series / B. Dell’osso [et al.] // Journal of Psychopharmacology (Oxford, England). - 2008. - Vol. 22. — №2. - P. 210-213.
90. Yeh Y.W. et al. High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission / Y.W. Yeh [et al.] // Clinical Neuropharmacology. - 2009. - Vol. 32. — №3. - P. 174-176.
91. Андриенко Е.В., Мосолова Е.С. Обсессивно-компульсивная симптоматика, индуцированная применением клозапина (алгоритм коррекции) // Современная терапия психических расстройств. – 2023. – No 3. – с. 22–31.DOI: 10.21265/PSYPH.2023.46.45.003
92. Abramowitz J.S. Understanding and treating obsessive-compulsive disorder: A cognitive- behavioral approach / J.S. Abramowitz - Mahwah, New Jersey: Erlbaum, 2006.
93. Wilhelm S. Cognitive therapy for obsessive-compulsive disorder: A guide for professionals / S. Wilhelm, G. Steketee - Oakland: New Harbinger. — 2006.
94. Clark D.A. Cognitive-behavioral therapy for OCD / D.A. Clark — New York: Guilford Press. — 2004.
95. Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and meta-analysis of studies published 1993-2014 / L.G. Ost [et al.] // Clinical Psychology Review. - 2015. - Vol. 40. - P. 156-169.
96. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment / N.H. Tenneij [et al.] // The Journal of Clinical Psychiatry. - 2005. - Vol. 66. — №9. - P. 1169-1175.
97. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder / H.B. Simpson [et al.] // The American Journal of Psychiatry. - 2008. - Vol. 165. — №30. — P. 621-630.
98. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders — first revision / B. Bandelow [et al.] // The World Journal of Biological Psychiatry. - 2008. - Vol. 9. — №4. - P. 248-312.
99. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Obsessive-Compulsive Disorder / Eds.: Koran LM, Hanna GL, Hollander E, et al./ American Psychiatric Association - Arlington. — 2007.
100. Abramowitz J.S. Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions / J.S. Abramowitz, E.B. Foa, M.E. Franklin // Journal of Consulting and Clinical Psychology. - 2003. - Vol. 71. - P. 394.
101. Refractory obsessive-compulsive disorder: state-of-the-art treatment / E. Hollander [et al.] // The Journal of Clinical Psychiatry. - 2002. - Vol. 63. - №6. - P. 20-29.
102. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo / W.K. Goodman [et al.] // Archives of General Psychiatry. - 1989. - Vol. 46. - №1. - P. 36-44.
103. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients / D. Marazziti [et al.] // CNS Spectrums. - 2008. - Vol. 13. - №11. - P. 971-976.
104. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs) / L. Ravizza [et al.] // Psychopharmacology Bulletin. - 1996. - Vol. 32. - №1. - P. 167-173.
105. Мосолов С.Н., Костюкова Е.Г., Сердитов О.В. Cеротониновый синдром при лечении депрессии. // Международный журнал медицинской практики. 2000. -№ 8.- С. 28-33.
106. Ravindran L.N. Intravenous anti-obsessive agents: a review / L.N. Ravindran, S.M. Jung, A.V. Ravindran // The Journal of Psychopharmacology (Oxford). - 2010. - Vol. 24. - №3. - P. 287-296.
107. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study / B.A. Fallon [et al.] // Archives of General Psychiatry. - 1998. - Vol. 55. - №10. - P. 918-924.
108. Koran L.M. Rapid benefit of intravenous pulse loading of clomipramine in obsessivecompulsive disorder / L.M. Koran, F.R. Sallee, S. Pallanti // The American Journal of Psychiatry. - 1997. - Vol. 154. - №3. - P. 396-401.
109. High-dose sertraline strategy for nonresponders to acute treatment for obsessivecompulsive disorder: a multicenter double-blind trial / P.T. Ninan [et al.] // The Journal of Clinical Psychiatry. - 2006. - Vol. 67. - №1. - P. 15-22.
110. Rabinowitz I. High-dose escitalopram for the treatment of obsessive-compulsive disorder / I. Rabinowitz, Y. Baruch, Y. Barak // International Clinical Psychopharmacology. - 2008. - Vol. 23. - №1. - P. 49-53.
111. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder / D.D. Dougherty [et al.] // International Clinical Psychopharmacology. - 2009. - Vol. 24. - №6. - P. 306-311.
112. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder / L.M. Koran [et al.] // The American Journal of Psychiatry. - 2002. - Vol. 159. - №1. - P. 88-95.
113. Pharmacological treatment strategies in obsessive compulsive disorder: A crosssectional view in nine international OCD centers / M. Van Ameringen [et al.] // The Journal of Psychopharmacology (Oxford). - 2014. - Vol. 28. - №6. - P. 596-602.
114. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review / U. Albert [et al.] // International Clinical Psychopharmacology. - 2016. -Vol. 31. - №5. - P. 249-258.
115. A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy / U. Albert [et al.] // Current Medicinal Chemistry. - 2018. - Vol. 25. - №41. - P. 5647-5661.
116. Second-generation antipsychotics for obsessive compulsive disorder / K. Komossa [et al.] // Cochrane Database Systematic Review. - 2010. - Vol. 12. - №12. - CD008141.
117. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo- controlled trials / M. Dold [et al.] // The International Journal of Neuropsychopharmacology. - 2013. - Vol. 16. - №3. - P. 557-574.
118. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials / M. Dold [et al.] // The International Journal of Neuropsychopharmacology. - 2015. - Vol. 18. - №9. - 436-448
119. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder / C.J. McDougle [et al.] // Archives of General Psychiatry. - 2000. - Vol. 57. - №8. - P. 794-801.
120. Cognitive-behavioral therapy vs. risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial / H.B. Simpson [et al.] // JAMA Psychiatry. - 2013. - Vol. 70. - №11. - P. 1190-1199.
121. Effects of aripiprazole augmentation in treatment-resistant obsessive- compulsive disorder (a double-blind clinical trial) / M. Sayyah [et al.] // Depression and Anxiety. - 2012. - Vol. 29. - №10. - P. 850-854.
122. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive- compulsive disorder / Storch, E.A. [et al.] // The Journal of Clinical Psychiatry. - 2013. - Vol. 74. - №6. - P. e527-e532.
123. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in
refractory obsessive-compulsive disorder: a crossover study / X. Li [et al.] // The Journal of Clinical Psychiatry. - 2005. - Vol. 66. - №6. - P. 736-743.
124 . Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial / O. Metin [et al.] // Human Psychopharmacology. - 2003. - Vol. 18. - №6. - P. 463-467.
125. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol / A.R. Sa [et al.] // Comprehensive Psychiatry. - 2009. - Vol. 50. - №5. - P. 437-442.
126. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic crosssectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients / A.A. Scheltema Beduin [et al.] // The Journal of Clinical Psychiatry. - 2012. - Vol. 73. - №11. - P. 1395-1402.
127. Relationship of obsessive-compulsive symptoms/disorder with clozapine: A retrospective study from a multispeciality tertiary care centre / S. Grover [et al.] // Asian Journal of Psychiatry. - 2015. - Vol. 15. - P. 56-61.
128. Double-blind, placebo-controlled trial of topiramate augmentation in treatmentresistant obsessive-compulsive disorder / H.A. Berlin [et al.] // The Journal of Clinical Psychiatry. - 2011. - Vol. 72. - №5. - P. 716-721.
129. Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial / A. Mowla [et al.] // CNS Spectrum. - 2010. - Vol. 15. - №11. - P. 613617.
130. opiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial / H. Afshar [et al.] // Journal of Research in Medical Sciences. - 2014. - Vol. 19. - №10. - P. 976-981.
131.Uzun O. Lamotrigine as an augmentation agent in treatment resistant obsessivecompulsive disorder: a case report / O. Uzun // The Journal of Psychopharmacology (Oxford). - 2010. - Vol. 24. - №3. - P. 425-427.
132. Arrojo-Romero M. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and longterm treatment-resistant obsessive-compulsive disorder / M. Arrojo- Romero, M. Tajes Alonso, J. de Leon // Case Reports Psychiatry. - 2013. - Vol. 2013.
133. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study / A. Bruno [et al.] // The Journal of Psychopharmacology (Oxford). - 2012. - Vol. 26. - №11. - P. 1456-1462.
134. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial / M. Khalkhali [et al.] // Iranian Journal of Psychiatry. - 2016. - Vol. 11. - №2. - P. 104-114.
135. Onder E. Does gabapentin lead to early symptom improvement in obsessivecompulsive disorder? / E. Onder, U. Tural, M. Gokbakan // The European Archives of Psychiatry and Clinical Neuroscience. - 2008. - Vol. 258. - №6. - P. 319-323.
136. Мосолов С.Н. Клиническое применение современных антидепрессантов. М. Мединформ.- 1995, 576 с.
137. Katzman M.A., Bleau P., Blier P. et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1.
138. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation / L.M. Koran [et al.] // The Journal of Clinical Psychiatry. - 2005. - Vol. 66. - №4. - P. 515-520.
139. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study / S. Pallanti [et al.] // CNS Drugs. - 2009. - Vol. 23. - №12. - P. 1047-1055.
140. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation / S. Pallanti [et al.] // European Neuropsychopharmacology. - 2014. - Vol. 24. - №3. - P. 375-380
141. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder / F. Soltani [et al.] // Human Psychopharmacology. - 2010. - Vol. 25. - №6. - P. 509-513.
142. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder / M. Heidari [et al.] // International Clinical Psychopharmacology. - 2014. - Vol. 29. - №6. - P. 344-350.
143. Andrade C. Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder / C. Andrade // The Journal of Clinical Psychiatry. - 2015. - Vol. 76. - №1. - P. e72-e75.
144. Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond / N.A. Fineberg [et al.] // Australian and New Zealand Journal of Psychiatry. - 2012. - Vol. 47. - №2. - P. 121-141.
145. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD) / A. Del Casale [et al.] // Current Neuropharmacology. - 2019. - Vol. 17. - №8. - P. 1-27.
146. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study / A. Ghaleiha [et al.] // Journal of Psychiatric Research. - 2013. - Vol. 47. - №2. - P. 175-180.
147. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD) / M. Haghighi [et al.] // Psychopharmacology (Berl.). - 2013. - Vol. 228. - №4. - P. 633-640.
148. Memantine augmentation improves symptoms in serotonin reuptake inhibitorrefractory obsessive-compulsive disorder: a randomized controlled trial / A. Modarresi [et al.] // Pharmacopsychiatry. - 2018. - Vol. 51. - №6. - P. 263-269.
149. Current status of deep brain stimulation for obsessive-compulsive disorder: a clinical review of different targets / P.P. de Koning [et al.] // Current Psychiatry Reports. - 2011. - Vol. 13. - №4. - P. 274-282.
150. Deep brain stimulation for refractory obsessive-compulsive disorder / J.L. Abelson [et al.] // Biological Psychiatry. - 2005. - Vol. 57. - №5. - P. 510-516.
151. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessivecompulsive disorder / D. Denys [et al.] // Archives of General Psychiatry. - 2010. - Vol. 67. - №10. - P. 1061-1068
152. Мосолов С.Н. Современные тенденции в терапии обсессивно-компульсивного расстройства: от научных исследований к клиническим рекомендациям //
Биологические методы терапии психических расстройств (доказательная медицина - клинической практике) / Под ред. С.Н. Мосолова. - М.: Социально-политическая мысль. - 2012. - С. 669-702.
153. Волель Б.А. Современные психофармакологические подходы в лечении обсессивно-компульсивных расстройств / Б.А. Волель // Психиатрия и психофармакотерапия. — 2002. — № 3. — С. 104-106.
154. Мосолов С.Н. Алгоритм биологической терапии обсессивно-компульсивного расстройства / Мосолов С.Н., Алфимов П.В. // Современная терапия психических расстройств. - 2013. - №1. - С. 41-44.
155. Капилетти С. Г., Цукарзи Э. Э., Мосолов С. Н. Монотерапия транскраниальной магнитной стимуляцией депрессивных и обсессивно-компульсивных состояний // Новые достижения в терапии психических заболеваний / Под. ред. С.Н. Мосолова. — М.: Бином. - 2002. — С. 593-605.
156. Seibell P.J. Management of obsessive-compulsive disorder / P.J. Seibell, E. Hollander // F1000 Prime Reports. - 2014. - Vol. 6. - P. 68
157. Mavrogiorgou P, Bader A, Stockfleth E, Juckel G. Obsessive-compulsive disorder in dermatology. // J Dtsch Dermatol Ges. - 2015. - Vol. 13. - №10. -P. 991-999.
158. Fluoxetine Dosage in OCD. [Электронный ресурс]. URL:
https://www.drugs.com/dosage/fluoxetine.html (дата обращения 10.11.2019)
159. Инструкция по применению эсциталопрама. [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=73f4317b-f057-49a5-b3b9- 2966331fe49b&t= (дата обращения 10.11.2019)
160. Fluvoxamine Dosage in OCD. [Электронный ресурс]. URL: https://www.drugs.Com/dosage/fluvoxamine.html#Usual Adult Dose for Obsessive Co mpulsive Disorder
161.Paroxetine Dosage in OCD. [Электронный ресурс]. URL: https://www.drugs.Com/dosage/paroxetine.html#Usual Adult Dose for Obsessive Com pulsive Disorder (дата обращения 10.11.2019)
162. Sertraline Dosage in OCD. [Электронный ресурс]. URL:https://www.drugs.Com/dosage/sertraline.html#Usual Adult Dose for Obsessive Comp ulsive Disorder
163. Clomipramine Dosage in OCD. [Электронный ресурс]. URL: https://www.drugs.Com/dosage/Clomipramine.html#Usual_Adult_Dose_for_Obsessive_C ompulsive_Disorder
164. Инструкция по применению кломипрамина. Таблетки. [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/Grls View v2.aspx?routingGuid=4bebd5ce-8555-45a7- 86fb-861c193aa096&t=
165. Venlafaxine Dosage. [Электронный ресурс]. URL:https://www.drugs.com/dosage/venlafaxine.html (дата обращения 10.11.2019)
166. Duloxetine Dosage. [Электронный ресурс]. URL:https://www.drugs.com/search.php?earchterm=duloxetine&a=1
167. Кирилочев О.О. Осложнения терапии клозапином: актуализация информации // современная терапия психических расстройств. – 2023. – No 3. – с. 12–20. – DOI: 10.21265/PSYPH.2023.11.37.002
168. Инструкция по применению кломипрамина. Ампулы. [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/Grls View v2.aspx?routingGuid=5341db46-fc2f-43b4- 9bc1-42daaafb6d61&t=
169. Haloperidol Dosage. [Электронный =ресурс]. URL:https7/wwwdugscom/searchphp?
170. Салахова А.И., Ягубов М.И. Сексуальная дисфункция при применении антидепрессантов у пациентов с тревожными и депрессивными расстройствами (алгоритм ведения и коррекции) // Современная терапия психических расстройств. — 2024. — No 2. — С. 56–67. — DOI: 10.21265/PSYPH.2024.31.31.006
171. Мосолов С.Н. Основы психофармакотерапии. М., Восток. - 1996, 276 с.
172. Risperidone Dosage. [Электронный ресурс]. URL:https://www.drugs.com/search.php?searchterm=risperidone&a=1 (дата обращения 10.11.2019)
173. Aripiprazole Dosage. [Электронный ресурс]. URL:https://www.drugs.com/search.php?searchterm=aripiprazole&a=1 (дата обращения 10.11.2019)
174. Quetiapine Dosage.[Электронный ресурс]. URL:https://www.drugs.com/search.php?searchterm=quetiapine&a=1
175. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. // Int Clin Psychopharmacol 2002; Vol.17, - P. 115-119.
176.Olanzapine Dosage. [Электронный ресурс]. URL:https7/wwwJdrugs1com/searchphp?searchterm=olanzapine&a=1.
177. PaliperidoneDosage. [Электронный ресурс]. URL:https://www.drugs.com/search.php?searchterm=paliperidone&a=1
178. Инструкция по применению амисульприда. [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/Grls View v2.aspx?routingGuid=d48f7ec2-6683-4fe9-a2c9- f36a1ee8d60a&t=
179. Topiramate Dosage. [Электронный ресурс]. URL:https7/www.dugsJcomsearchphp?searchterm=topiramate&a=1.
180. Lamotrigine Dosage.[Электронный ресурс]. URL:https7/www.dugsJcom/searchphp?searchterm=lamotrigine&a=1.
181. Gabapentin Dosage [Электронный ресурс]. URL:https7/www.dugsJcomsearchphp?searchterm=gabapentin&a=1
182. Mirtazapine Dosage. [Электронный ресурс]. URL: https://www.drugs.com/search.php?searchterm=mirtazapine&a=1
183.Малин Д.И., Рывкин .В., Булатова Д.Р. Синдром удлиненного интервала QT при применении антипсихотических и антидепрессивных препаратов // Современная терапия психических расстройств. – 2023. – No 2. – С. 48–56. – DOI: 10.21265/PSYPH.2023.69.57.006
184.MemantineDosage. [Электронныйресурс]. URL: https://www.drugs.com/ search.php? searchterm=memantine&a=1 (
185.Stein DJ, Costa DLC, Lochner C, et al. Obsessive-compulsive disorder. // Nat Rev Dis Primers. -2019. - Vol. 5. - N1. - P. 52-68
186. Kayser R.R. Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder. // J Clin Psychiatry. - 2020. - Vol.81 - N5- P. 19ac13182.
https://doi.org/10.4088/JCP.19ac13182
187. Bloch M.H., McGuire J., Landeros-Weisenberger A., et al. Meta-analysis of the doseresponse relationship of SSRI in obsessive-compulsive disorder. // Mol Psychiatry. - 2010. - Vol.15. - N8. - P.850-855.
188. Pittenger C., Bloch M.H. Pharmacological treatment of obsessive- compulsive disorder. // Psychiatr Clin North Am. -2014.- Vol.37. - N3. - P. 375-391.
189. Fineberg N.A., Reghunandanan S., Simpson H.B. et al. Accreditation Task Force of the Canadian Institute for Obsessive Compulsive Disorders. Obsessive-compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults. // Psychiatry Res. - 2015. - Vol.227. - N1. - P.114-125.
190. Beaulieu A.M., Tabasky E., Osser D.N. The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for adults with obsessive-compulsive disorder. // Psychiatry Res. - 2019, Vol. 28, P. 112583.
191. Bloch M.H., Landeros-Weisenberger A., Kelmendi B. et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive- compulsive disorder. // Mol Psychiatry. - 2006.- Vol.11. - N7. - P. 622-632.
192. Pittenger C. Glutamatergic agents for OCD and related disorders. // Curr Treat Options Psychiatry - 2015. - Vol.2. - P. 271-283.
193. Lafleur D.L., Pittenger C., Kelmendi B. et al. N-Acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. // Psychopharmacology (Berl). - 2006. - Vol.184. - P. 254-256.
194. Afshar H., Roohafza H., Mohammad-Beigi H. et al. N-Acetylcysteine add-on treatment in refractory obsessive- compulsive disorder: a randomized, double-blind, placebo-controlled trial. // J Clin Psychopharmacol. - 2012. - Vol.32. - P. 797-803.
195. Sarris J., Oliver G., Camfield D.A. et al. N-Acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16- week, double-blind, randomised, placebo-controlled study. // CNS Drugs. - 2015.- Vol. 29. - P. 801-809.
196. Couto J.P., Moreira R. Oral N-acetylcysteine in the treatment of obsessivecompulsive disorder: a systematic review of the clinical evidence. // Prog Neuropsychopharmacol Biol Psychiatry. - 2018. - Vol. 86, P. 245-254.
197. Становая В.В., Иванов М.В. Терапия обсессивно-компульсивных проявлений в структуре шизофренических расстройств // Современная терапия психических расстройств. – 2023. – No 3. – с. 3–11. – DOI: 10.21265/PSYPH.2023.24.86.001
198. Kishi T., Matsuda Y., Iwata N. Combination therapy of serotonin reuptake inhibitors and memantine for obsessive- compulsive disorder: a meta- analysis of double-blind, randomized, placebo-controlled trials. // J Alzheimers Dis. - 2018.- Vol. 64. - N1. - P. 4348.
199. Lusicic A., Schruers K.R.J., Pallanti S., et al. Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. // Neuropsychiatr Dis Treat. - 2018. - Vol. 14. - P. 1721-1736.
200. Carmi L., Tendler A., Bystritsky A. et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. // Am J Psychiatry. - 2019. - Vol.176. - N11. - P. 931-938.
201. Berlim M. T., Neufeld N. H., Van den Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory metaanalysis of randomized and sham-controlled trials // Journal of Psychiatric Research. - 2013 - № 8 (47). - P. 999-1006.
202. Trevizol A. P., Shiozawa P., Cook I. A., et al. Transcranial Magnetic Stimulation for
Obsessive-Compulsive Disorder: An Updated Systematic Review and Meta-analysis // The journal of ECT. - 2016 - № 4 (32). - P. 262-266.
203. Fineberg N. A., Hollander E., Pallanti S., et al. Clinical advances in obsessivecompulsive disorder: a position statement by the International College of ObsessiveCompulsive Spectrum Disorders // International Clinical Psychopharmacology. - 2020 - № 4 (35). - P. 173-193.
204.Rehn S., Eslick G. D., Brakoulias V. A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD) // The Psychiatric Quarterly. - 2018 - № 3 (89). - P. 645-665.
205. Grassi G., Pallanti S. Current and up-and-coming pharmacotherapy for obsessivecompulsive disorder in adults. // Expert Opin Pharmacother. - 2018. - Vol.19. - N14. -P. 1541-1550
206. Farris SG, McLean CP, Van Meter PE, et al. Treatment response, symptom remission and wellness in obsessive-compulsive disorder. // J Clin Psychiatry. - 2013.- Vol.74. - P. 685-690.
207. Diniz J.B., Shavitt R.G., Pereira C.A. et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessivecompulsive disorder: A randomized, open-label trial. // J Psychopharmacol. - 2010. - Vol. 24. - P. 297-307.
208. Veale D., Miles S., Smallcombe N. et al. Atypical antipsychotic augmentation in SSRI refractory obsessive-compulsive disorder: A systematic review and meta-analysis. //BMC Psychiatry. - 2014. - Vol.14. - P. 317-325.
209. Биологические методы терапии психических расстройств (доказательная медицина - клинической практике). /Под ред. С.Н. Мосолова/ - М., «Социально-политическая мысль», 2012, 1073 с.
210. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А. Г. Чучалина, Ю. Б. Белоусова, В. В. Яснецова. Москва, 2009. (10-е издание, переработанное и дополненное)
211. Askari N., Moin M., Sanati M. et al. Granisetron adjunct to fluvoxamine for moderate- to- severe obsessive-compulsive disorder. // CNS Drugs. - 2012. - Vol. 26. - P. 883-892.
212. Менделевич В.Д., Королева П.В., Нестерина М.К. Суицидальное и самоповреждающее поведение в ре- зультате приема антидепрессантов: факты и интерпретации // Современная терапия психических расстройств. — 2024. — No .3 — С. 70–76. — DOI: 10.21265/PSYPH.2024.87.39.007
213. Lopes A.C., Greenberg B.D., Canteras M.M. et al. Gamma ventral capsulotomy for obsessive-compulsive disorder. A randomized clinical trial. // J Am Med Ass Psychiatry. - 2014. - Vol.71. - 1066-1076.
214. Blom R.M., Figee M., Vulink T. et al. Electroconvulsive therapy, transcranial magnetic stimulation and deep brain stimulation in OCD. In: Zohar J (ed) Obsessive compulsive disorder: Current science and clinical practice. Chichester, West Sussex : Wiley-Blackwell, 2012, pp. 193-238.
215. Кекелидзе З.И., Мосолов С.Н., Цукарзи Э.Э., Оленева Е.В. Применение электросудорожной терапии в психиатрической практике. Учебно-методическое пособие для врачей. М., 2019, 32 с.
216. Blomstedt P., Sjoberg R.L., Hansson M. et al. Deep brain stimulation in the treatment of obsessive-compulsive disorder. // World Neurosurg.- 2013. - Vol. 80. - P. 245-253.
217. Mantione M., Nieman D.H., Figee M. et al. Cognitive-behavioural therapy augments the effects of deep brain stimulation in obsessive-compulsive disorder. // Psychol Med. - 2014. - Vol.25. - P. 1-8.
218. Perera M. P. N. et al. Electrophysiology of obsessive compulsive disorder: a systematic review of the electroencephalographic literature //Journal of anxiety disorders. - 2019. - Т. 62. - С. 1-14.
219. Yavuzkir M. F. et al. P wave dispersion in obsessive-compulsive disorder //Indian journal of psychiatry. - 2015. - Т. 57. - №. 2. - С. 196.
220. Mowla A., Boostani S., Dastgheib S. A. Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-blind controlled clinical trial //Journal of clinical psychopharmacology. - 2016. - Т. 36. - №. 6. - С. 720-723.
221. Петелин Д.С., Аведисова А.С., Иващенко Д.В., с соавт. Актуальные проблемы диагностики и терапии обсессивно-компульсивного расстройства // современная терапия психических расстройств. — 2024. — No 4. — с. 67–75. — DOI: 10.21265/PSYPH.2024.82.91.007
222. McDougle C. J. et al. A double blind placebo controlled study in patients with and without tics //Archives of General Psychiatry. - 1994. - Т. 51. - С. 302-308 37.
223. Bandelow B. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders / B. Bandelow, U. Seidler-Brandler, A. Becker et al. // World J. Biol. Psychiat. - 2007. - Vol. 8 (3). -Р .175-187.
224. Cuijpers Р. Эффективность психотерапии и фармакотерапии в лечении депрессивных и тревожных расстройств: мета-анализ прямых сравнительных исследований / P. Cuijpers, M. Sijbrandij, S. L. Kooleetal. // Всемирная психиатрия (на русском языке). - 2013. - Vol. 2. - Р. 130-141.- (World Psychiatry.- 2013. - Vol. 12. - P. 137-148).
225. Khoury B. Mindfulness-based therapy: a comprehensive meta-analysis / B. Khoury, T. Lecomte, G. Fortin et al. // Clin. Psychol. Rev. - 2013. - Vol. 33(6). - Р. 763-771. http://dx.doi.org/10.1016/j.cpr.2013.05.005
226. Бирюкова Е.В. Применение альфа-тета тренинга БОС при тревожных расстройствах, резистентных к психофармакотерапии (открытое рандомизированное, контролируемое исследование) / Бирюкова Е.В. Тимофеев И.В., Мосолов С.Н. // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. - 2010. - №1. - С.15-20.
227. Delle Chiaie R. et al. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study //Clinical practice and epidemiology in mental health: CP & EMH. - 2011. - Т. 7. - С. 107.
228. Carey P.D. et al. Quetiapine augmentation of SRIs in treatment refractory obsessivecompulsive disorder: a double-blind, randomised, placebo-controlled study
[ISRCTN83050762] // BMC Psychiatry. - 2005.- Т.5. - № 5. - С. 1-8
229. Pallanti S., Quercioli L., Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study //Journal of Clinical Psychiatry. - 2004. - Т. 65. - №. 10. - С. 1394-1399.
230. Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. 2001. Citalopram 20mg, 40mg and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 16:75-86.
231. Bandelow B. et al. (2022): WFSBP guidelines for treatment of anxiety, obsessivecompulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD, The World Journal of Biological Psychiatry, DOI: 10.1080/15622975.2022.2086296
232. Hoppen LM, Kuck N, Burkner PC, Karin E, Wootton BM, Buhlmann U. 2021. Low intensity technology-delivered cognitive behavioral therapy for obsessive-compulsive disorder: a meta-analysis. BMC Psychiatry. 21(1):322.
233. Marsden Z, Lovell K, Blore D, Ali S, Delgadillo J. 2018. A randomized controlled trial comparing EMDR and CBT for obsessive-compulsive disorder. Clin Psychol Psychother 25:e10-e18.
234. Малин Д.И., Рывкин П.В. Клинически значимые лекарственные взаимодействия при лечении антипсихотиками второго поколения // Современная терапия
психических расстройств. - 2021. - No 2. - С. 36-45 - DOI:10.21265/PSYPH.2021.57.2.005
235. Мосолов С.Н., Малин Д.И., Рывкин П.В., Сычев Д.А. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике // Современная терапия психических расстройств. 2019, S1, С. 2-35. DOI: 10.21265/PSYPH.2019.50.40828
236. Biria M, Huang F-X, Worbe Y, Fineberg NA, Robbins TW, Fernandez-Egea E. A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD. Eur Neuropsychopharmacol 2019;29:905-13. https7/doLorg/104016/jeuroneuro
237. Мосолов С.Н., Цукарзи Э.Э., Маслеников Н.В. Применение транскраниальной магнитной стимуляции в психиатрии. /под ред. С.Н. Мосолова / - Иваново: Нейрософт, 2023, 576 с.
238. Galkin M.V., Zaitsev O.S., Golanov A.V., Mosolov S.N., Poddubskaya A.A., Kostjuchenko V.V. Gamma Knife Capsulotomy for Correction of Obsessive-Compulsive Symptoms in a Patient with Schizophrenia: Case Report. // Progress in Brain Research, 2022;272(1):23-31 https://doi.org/10.1016/bs.pbr.2022.03.012
239. Wong, Shiu F., John H. Riskind, and Frederick Aardema, 'Prevention of ObsessiveCompulsive Disorder', in Eric A. Storch, Jonathan S. Abramowitz, and Dean McKay (eds), Complexities in Obsessive Compulsive and Related Disorders: Advances in Conceptualization and Treatment (New York, 2021; online edn, Oxford Academic, 1 Aug. 2021), https://doi.Org/10.1093/med-psych/9780190052775.003.0023, accessed 21 June 2023.
240. Приказ Минздрава России от 30.06.2022 № 453н «Об утверждении Порядка диспансерного наблюдения за лицом, страдающим хроническим и затяжным психическим расстройством с тяжелыми стойкими или часто обостряющимися болезненными проявлениями» www.pravo.gov.ru, 28.07.2022, N 0001202207280028.
241. Приказ Минздрава России от 05.07.2022 № 468н «Об утверждении стандарта медицинской помощи взрослым при обсессивно-компульсивном расстройстве (диагностика, лечение и диспансерное наблюдение)» www.pravo.gov.ru, 12.08.2022, N0001202208120007.
242. Приказ Минздрава России от 14.10.2022 № 668н «Об утверждении Порядка оказания медицинской помощи при психических расстройствах и расстройствах поведения» www.pravo.gov.ru, 14.11.2022, N 0001202211140024.
243. Brakoulias V, Perkes IE, Tsalamanios E. A call for prevention and early intervention in obsessive-compulsive disorder. Early Interv Psychiatry. 2018 Aug;12(4):572-577. doi: 10.1111/eip.12535. Epub 2017 Dec 14. PMID: 29239120.
244. Михеенкова Н.М., Рывкин П.В., Мосолов С.Н. Серотониновый синдром: клиника, патофизиология и терапия // Современная терапия психических расстройств. - 2022. - No 2. - С. 53-63. - DOI: 10.21265/PSYPH.2022.90.61.006
245. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59(4):165-171. doi:10.4088/jcp.v59n0404.
246. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). // Int Clin Psychopharmacol. 1996;11(4):247-254. doi:10.1097/00004850-199612000-00006.
247. Hollander E, DeCaria CM, Mari E, et al. Short-term single-blind fluvoxamine treatment of pathological gambling. // Am J Psychiatry. 1998;155(12):1781-1783. doi:10.1176/ajp.155.12.1781
248. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. // Biol Psychiatry. 2000;47(9):813-817. doi:10.1016/s0006-3223(00)00241-9
249.Posner K., Oquendo M.A., Gould M., Stanley B., Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA’s Pediaric Suicidal Risk Analysis of Antidepressants // Am J Psychiatry, 200; 164:1035- 1043.
250. Jimёnez E. et al. Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder //Acta Psychiatrica Scandinavica. - 2016. - Т. 133. - №. 4. - С. 266-276.
251. Phelps NJ, Cates ME. The role of venlafaxine in the treatment of obsessive-compulsive disorder. // Ann Pharmacother. 2005;39(1):136-40.
252. Федеральное руководство по использованию лекарственных средств (формулярная система) / под ред. А. Г. Чучалина, Ю. Б. Белоусова, В. В. Яснецова. Москва, 2012. (13-е издание, переработанное и дополненное), 970 с.
253. Khazaneha M, Bakhshinejad B, Mehrabani M, et al. Machine learning in obsessive-compulsive disorder medications. // Heliyon. 2024;10(21):e40136
254. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. // Arch Gen Psychiatry. 1994;51(4):302-8.
255. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int. 2019;116(20):355-361.
256. Tint A., Haddad P.M., Anderson I.M. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008; 22:330-332.
257. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67 Suppl 4:27-30.
258. Хасанова А. К., Мосолов С. Н. Синдромом отмены приема антидепрессантов (алгоритм профилактики и коррекции) // Современная терапия психических расстройств. - 2023. - No 2. - С. 37-47. - DOI: 10.21265/PSYPH.2023.15.79.005
259. Warner C.H., Bobo W., Warner C. et al. Antidepressant discontinuation syndrome // American Family Physician. - 2006. - Vol. 74 (3). - Pp. 449-456.
260. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. // Dtsch Arztebl Int. 2019;116(20):355-361
261. Patil P, Schwartz TL. Fine Tuning the Use of Second Generation Antipsychotics. // J Ment Health Clin Psychol 2018;2(5): 22-39.
262. Бирюкова Е.Г., Мосолов С.Н. Прогноз эффективности нейрофидбека у больных тревожными расстройствами, резистентными к психофармакотерапиию // Социальная и клиническая психиатрия. – 2011; Том 21, вып.2, с. 75-81
263. Pampaloni, Ilenia et al. The global assessment of OCD. // Comprehensive psychiatry vol. 118 (2022): 152342. doi:10.1016/j.comppsych.2022.152342